期刊
NATURE REVIEWS CANCER
卷 18, 期 4, 页码 255-263出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrc.2017.125
关键词
-
类别
资金
- Koch Institute-Dana-Farber/Harvard Cancer Center Bridge Project
- National Cancer Institute (NCI) [R33 CA191143]
- NCI Cancer Systems Biology Consortium [U54 CA217377]
- NCI [K08 CA212252]
Therapeutics that block kinases, transcriptional modifiers, immune checkpoints and other biological vulnerabilities are transforming cancer treatment. As a result, many patients achieve dramatic responses, including complete radiographical or pathological remission, yet retain minimal residual disease (MRD), which results in relapse. New functional approaches can characterize clonal heterogeneity and predict therapeutic sensitivity of MRD at a single-cell level. Preliminary evidence suggests that iterative detection, profiling and targeting of MRD would meaningfully improve outcomes and may even lead to cure.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据